This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Abiomed Management

Management criteria checks 3/4

Key information

Mike Minogue

Chief executive officer

US$12.7m

Total compensation

CEO salary percentage	6.2%
CEO tenure	18.7yrs
CEO ownership	0.8%
Management average tenure	4.5yrs
Board average tenure	8.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mike Minogue's remuneration changed compared to Abiomed's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	US$267m
Jun 30 2022	n/a	n/a	US$218m
Mar 31 2022	US$13m	US$789k	US$137m
Dec 31 2021	n/a	n/a	US$133m
Sep 30 2021	n/a	n/a	US$149m
Jun 30 2021	n/a	n/a	US$154m
Mar 31 2021	US$15m	US$608k	US$226m
Dec 31 2020	n/a	n/a	US$200m
Sep 30 2020	n/a	n/a	US$208m
Jun 30 2020	n/a	n/a	US$159m
Mar 31 2020	US$17m	US$768k	US$203m
Dec 31 2019	n/a	n/a	US$245m
Sep 30 2019	n/a	n/a	US$221m
Jun 30 2019	n/a	n/a	US$258m
Mar 31 2019	US$19m	US$753k	US$259m
Dec 31 2018	n/a	n/a	US$222m
Sep 30 2018	n/a	n/a	US$190m
Jun 30 2018	n/a	n/a	US$165m
Mar 31 2018	US$10m	US$718k	US$112m
Dec 31 2017	n/a	n/a	US$90m
Sep 30 2017	n/a	n/a	US$92m
Jun 30 2017	n/a	n/a	US$77m
Mar 31 2017	US$12m	US$649k	US$52m
Dec 31 2016	n/a	n/a	US$48m
Sep 30 2016	n/a	n/a	US$43m
Jun 30 2016	n/a	n/a	US$42m
Mar 31 2016	US$19m	US$630k	US$38m

Compensation vs Market: Mike's total compensation ($USD12.67M) is above average for companies of similar size in the UK market ($USD5.41M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.

CEO

Mike Minogue (55 yo)

18.7yrs

Tenure

US$12,665,992

Compensation

Mr. Michael R. Minogue, also known as Mike, served as Director at Medical Device Innovation Consortium, previously served as its chairman until June 2019. He has been Chief Executive Officer and President...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Minogue	Chairman	18.7yrs	US$12.67m	0.77% $ 133.2m
Todd Trapp	Executive VP & CFO	4.7yrs	US$3.04m	0.017% $ 2.9m
Marc Began	Executive VP	4.5yrs	US$2.57m	0.027% $ 4.7m
Andrew Greenfield	Executive VP & Chief Commercial Officer	2.7yrs	US$2.84m	0.045% $ 7.8m
David Weber	Scientific & Technology Advisor	less than a year	US$2.29m	0.30% $ 52.2m
Matthew Plano	Executive Vice President of Global Operations & Integration	no data	no data	0.017% $ 3.0m
Thorsten Siess	Executive VP & Chief Technology Officer	no data	no data	no data
Ingrid Ward	Director of Investor Relations	8.3yrs	no data	no data
Sarah Karr	Communications Manager	no data	no data	no data
Michael Howley	VP & GM of Global Sales	13.8yrs	US$1.71m	no data
Karen Mahoney	VP & Chief Human Resources Officer	3.3yrs	no data	no data
Charles Simonton	Executive VP & Chief Medical Officer	2.5yrs	no data	no data

4.5yrs

Average Tenure

55yo

Average Age

Experienced Management: 0H7S's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Minogue	Chairman	18.7yrs	US$12.67m	0.77% $ 133.2m
Martin Sutter	Independent Director	14.6yrs	US$266.80k	0.26% $ 45.2m
Jeannine Rivet	Independent Director	6.8yrs	US$266.80k	0.021% $ 3.5m
Paul Thomas	Independent Director	11.6yrs	US$269.30k	0.013% $ 2.2m
Eric Rose	Independent Director	8.3yrs	US$259.30k	0.032% $ 5.5m
Dorothy Puhy	Independent Lead Director	19.3yrs	US$299.30k	0.032% $ 5.4m
Paula Johnson	Independent Director	1.7yrs	US$499.89k	0.0011% $ 190.8k
Christopher Van Gorder	Independent Director	6.8yrs	US$264.30k	0.015% $ 2.6m
Myron Rolle	Independent Director	1.8yrs	US$259.30k	0.0011% $ 195.9k

8.3yrs

Average Tenure

67yo

Average Age

Experienced Board: 0H7S's board of directors are considered experienced (8.3 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/12/24 09:10
End of Day Share Price	2022/12/22 00:00
Earnings	2022/09/30
Annual Earnings	2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abiomed, Inc. is covered by 26 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Lawrence Neibor	Baird
Jan Wald	Benchmark Company
Michael Gorman	BTIG

This company listing is no longer active

Abiomed Management

Management criteria checks 3/4

Key information

Recent management updates

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold US$1.2m worth of stock

Independent Director recently sold US$5.1m worth of stock

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Second quarter 2023 earnings released: EPS: US$2.34 (vs US$1.25 in 2Q 2022)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold US$1.2m worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold US$5.1m worth of stock

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Revenue beats expectations

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Revenue beats expectations

Abiomed, Inc. to Report Q3, 2021 Results on Jan 28, 2021

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources